AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02122432 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Teledermatology
Description: General practitioner takes 3 photographs per dermatologic lesion using either a telephone with a 3Mega Pixel minimum camera or a standard camera following recommendations of the practice guidelines for teledermatology (2007) of the American Telemedicine Association.~Photographs are sent by email using a secured mail server with at least the following information=date of symptoms, symptomatology, topography of lesions, description of lesions, extension, recent drug intakes)~Photographs are read and analyzed by a single dermatologist who gives an expert answer (diagnosis and/or treatment). Answer is sent back to the general practitioner by email (using a secured mail server). Answer contains at least the following information= are photographs usable? What is the diagnosis? If necessary, which treatment should the general practitioner begin ? If necessary, does the patient need a consultation with a dermatologist ?
Study NCT02029170 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early weightbearing
Description: Patients allocated to early weightbearing group are allowed to weightbear after stitch out and application of a walking cast
Study NCT02029170 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-weightbearing
Description: Patients allocated to non-weightbearing group are kept non-weightbearing till 6 weeks post-operative
Study NCT02140242 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: study part 1 - dose daunorubicin
Description: standard induction dose of daunorubicin 60 mg/m2 on days 3-5
Study NCT02140242 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: induction cycles
Description: single induction cycle versus double induction cycles (only patients with good response after first induction) Allocation is randomized for cytogenetic risk.
Study NCT02140242 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: induction cycles
Description: single induction cycle versus double induction cycles (only patients with good response after first induction) Allocation is randomized for cytogenetic risk.
Study NCT02474654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epimorphine
Description: 150mcg
Study NCT04162509 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AR app
Description: Participants will be exposed to nine different AR spider scenarios with a pre-defined length of 2 minutes for each level. Each level starts with a surface scan of the environment and the placement of the AR spider model(s) by tapping on the display. Through small text pop-ups the user is instructed to perform different tasks (e.g. looking at the spider model, approaching it, holding the hand under the model). They proceed to further levels according to a predefined exposure scheme based on SUDS for fear (scale 0=no fear to 10=maximum fear) and disgust (scale 0=no disgust to 10=maximum disgust) and the assurance of the task completed (yes/no). Users will repeat each level until their SUDS are 4 or below and have completed the task. Each exposure session is limited to approx. 30 minutes (controlled by the participants) irrespective of achieved level.
Study NCT05181306 — intervention group
Intervention type: PROCEDURE
Intervention: Robotic-assisted Total Gastrectomy with D2 Lymphadenectomy
Description: Robotic-assisted total gastrectomy with D2 lymph node dissection will be performed with curative treated intent according to the patients' or their legal representatives'willing to choose robotic-assisted total gastrectomy and excluding T4b、bulky lymph nodes or distant metastasis case by diagnostic laparoscopy. The alimentary canal reconstruction method is selected as esophageal jejunal R-Y anastomosis. Whether to reinforce the anastomotic manually is decided by the surgeon's experience. The reconstruction can be carried out by extracorporeal or intracorporeal anastomosis.
Study NCT05181306 — intervention group
Intervention type: PROCEDURE
Intervention: Laparoscopic-assisted Total Gastrectomy with D2 Lymphadenectomy
Description: Laparoscopic-assisted total gastrectomy with D2 lymph node dissection will be performed with curative treated intent according to the patients' or their legal representatives'willing to choose laparoscopic-assisted total gastrectomy and excluding T4b、bulky lymph nodes or distant metastasis case by diagnostic laparoscopy. The alimentary canal reconstruction method is selected as esophageal jejunal R-Y anastomosis. Whether to reinforce the anastomotic manually is decided by the surgeon's experience. The reconstruction can be carried out by extracorporeal or intracorporeal anastomosis.
Study NCT00471640 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone
Description: 4 days 5 mg
Study NCT00471640 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: dexamethasone
Description: 4 days 5 mg
Study NCT02492594 — intervention group
Intervention type: OTHER
Intervention: Peripheral blood sampling
Description: Peripheral blood samples will be taken at 3-5 defined timepoints during febrile neutropenia:~* at the start of neutropenic fever~* after 24 hours~* after 48 hours~* before the start of antimycotic therapy, if pertinent~* at the end of antimycotic therapy, if pertinent
Study NCT02474654 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epimorphine
Description: 150mcg
Study NCT02474654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal Saline
Description: 0.3 ml
Study NCT02474654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal Saline
Description: 30ml
Study NCT02224833 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pharmacist intervention
Description: Systematic review of treatments:~Identification of reasons for PPI.~* Determination of recommended pharmacotherapeutic alternatives.~* Issue recommendations for therapeutic appropriateness to the doctor (via registration on the EHR and verbal communication if deemed appropriate); that will be of 4 types: Add medicine, discontinue medicine, adjust dosage, replace medicine.~After the medical visit (the next day) New treatment review for: Checking acceptance or rejection of the recommendations issued, review potential new prescriptions made without pharmacist recommending, and whether these new drugs lead to PIP.
Study NCT02474654 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline
Description: 30ml
Study NCT02474654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal Saline
Description: 100 ml
Study NCT03866460 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Distortion product otoacoustic emission measurement (DPOAE)
Description: Hearing will be measured at baseline and 3-9 months after completion of treatment with IA carboplatin chemotherapy.
Study NCT03769298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Envarsus XR
Description: The Envarsus XR® drug will be administered to study participants once daily, orally. The dosage can be 0.75 mg, 1 mg or 4 mg. The tacrolimus whole blood trough concentrations will be monitored and titrate Envarsus XR® dosage to achieve target whole blood trough concentration.
Study NCT03862859 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Dose adjusted Warfarin targeting an international normalized ratio of 2-3.
Study NCT03025009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3192767
Description: Administered SC.
Study NCT03025009 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Basal Insulin Peglispro
Description: Administered SC.
Study NCT03025009 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine
Description: Administered SC.
Study NCT02474654 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline
Description: 100 ml
Study NCT02474654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivicaine
Description: 100 ml
Study NCT02474654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine
Description: 600 mcg
Study NCT02474654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: 30 mg
Study NCT02474654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivicaine with Epinephrine
Description: 0.5% 1:400,000 30ml
Study NCT03993639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Single dose of SC administration
Study NCT00040794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV
Study NCT00040794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV
Study NCT00040794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gefitinib
Description: Given PO
Study NCT00040794 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiotherapy
Study NCT00040794 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Optional correlative studies
Study NCT00142116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: 200mg orally once a day for 14 weeks if that dosage is tolerated well, it will be increased to 400mg for up to 50 weeks.
Study NCT00142116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given intravenously once weekly for 4 weeks beginning the second week of study treatment. If tolerated well, this may be repeated 8 weeks later.
Study NCT00979212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: panitumumab
Description: Induction: 2.5 mg/kg, IV, days 1, 8, 15, 22, 29, 36 of radiation therapy before administration of chemotherapy and radiation therapy.
Study NCT00979212 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin
Description: Induction: AUC=2, IV, days 1, 8, 14, 22, 29, and 36 of radiation therapy. Consolidation, 6-12 weeks following surgery, AUC=6, IV, days 1 and 22.
Study NCT00979212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Induction: AUC=2, IV, days 1, 8, 14, 22, 29, and 36 of radiation therapy. Consolidation, 6-12 weeks following surgery, AUC=6, IV, days 1 and 22.
Study NCT00979212 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: Induction: 50 mg/m2, IV, days 1, 8, 14, 22, 29, and 36 of radiation therapy. Consolidation, 6-12 weeks following surgery, 200 mg/m2, IV, days 1 and 22.
Study NCT00979212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Induction: 50 mg/m2, IV, days 1, 8, 14, 22, 29, and 36 of radiation therapy. Consolidation, 6-12 weeks following surgery, 200 mg/m2, IV, days 1 and 22.
Study NCT00979212 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgery
Description: A lobectomy or pneumonectomy performed 4-6 weeks after completion of induction chemoradiation
Study NCT00979212 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery
Description: A lobectomy or pneumonectomy performed 4-6 weeks after completion of induction chemoradiation
Study NCT02786927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo ELLIPTA device
Description: Placebo ELLIPTA is a DPI device containing powder for inhalation, to be inhaled orally once daily for 5-9 days. It contains two strips with 30 blisters per strip - one strip contains lactose monohydrate whereas the other strip contains lactose monohydrate blended with magnesium stearate.
Study NCT02786927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo capsules for use in HANDIHALER device
Description: Placebo capsules contain lactose monohydrate in the form of powder for inhalation, to be used with the HANDIHALER inhaler as an oral inhalation once daily for 5-9 days.
Study NCT02615613 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Acceptability Meal
Study NCT02615613 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High acceptability meal
Study NCT02800785 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefoxitin, Ertapenem, Moxifloxacin, Tigecycline, Ticarcillin-Clavulanic Acid; Metronidazole plus Cefazolin, Cefuroxime, Ceftriaxone, Cefotaxime, Ciprofloxacin, or Levofloxacin
Description: Patients will be offered a treatment regimen of antibiotics based on guidelines published jointly by the Surgical Infection Society and the Infectious Disease Society of America. After IV antibiotics are administered for a period of at least 24 hours, a regimen of oral antibiotics will be continued for a total treatment length of 10 days. Preferred oral antibiotic regimens include Moxifloxacin alone, and combinations such as Metronidazole or Clindamycin, for anaerobic bacteria coverage, plus Ciprofloxacin or Levofloxacin, or an oral Cephalosporin for aerobic Gram-negative bacteria coverage.
Study NCT02800785 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Appendectomy
Description: Appendectomy will be performed by an open or laparoscopic approach, depending on patient and surgeon preference.
Study NCT01790191 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Repeated consumption of basic artichoke purée.
Description: In this conditioning trial, the effect of repeated consumption of different types of artichoke purée was studied. In Arm 1, participants were repeatedly exposed to basic artichoke purée. In Arm 2, participants were repeatedly exposed to sweet artichoke purée. In Arm 3, participants were repeatedly exposed to fat artichoke purée. Change in intake and liking of basic artichoke purée was evaluated at baseline and after 10 exposures to artichoke purée ; and at 3 follow-ups: after 2 weeks (FU2W), after 3 months (FU3M) and after 6 months (FU6M).
Study NCT01790191 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Repeated consumption of sweet artichoke purée.
Description: In this conditioning trial, the effect of repeated consumption of different types of artichoke purée was studied. In Arm 1, participants were repeatedly exposed to basic artichoke purée. In Arm 2, participants were repeatedly exposed to sweet artichoke purée. In Arm 3, participants were repeatedly exposed to fat artichoke purée. Change in intake and liking of basic artichoke purée was evaluated at baseline and after 10 exposures to artichoke purée ; and at 3 follow-ups: after 2 weeks (FU2W), after 3 months (FU3M) and after 6 months (FU6M).
Study NCT01790191 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Repeated exposure to fat artichoke purée.
Description: In this conditioning trial, the effect of repeated consumption of different types of artichoke purée was studied. In Arm 1, participants were repeatedly exposed to basic artichoke purée. In Arm 2, participants were repeatedly exposed to sweet artichoke purée. In Arm 3, participants were repeatedly exposed to fat artichoke purée. Change in intake and liking of basic artichoke purée was evaluated at baseline and after 10 exposures to artichoke purée ; and at 3 follow-ups: after 2 weeks (FU2W), after 3 months (FU3M) and after 6 months (FU6M).
Study NCT00778401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin tablets 800 mg
Study NCT00778401 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin tablets 800 mg
Study NCT03403179 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Remediation
Description: Functional Remediation: The functional remediation program consists of 21 weekly sessions, each lasting 90 min. This intervention addresses neurocognitive issues such as attention, memory and executive functions, but it focuses even more on enhancing functioning in daily routine. The content of the intervention is based on ecological tasks to be performed in two settings, in the clinic as well as at home. Participants will be trained with exercises for memory, attention, problem solving and reasoning, multitasking and organization in order to improve their functional outcome. Most of the techniques are based on paper-and-pencil tasks and group activities.
Study NCT01189721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol, sevoflurane
Description: Remifentanil will be infused intraoperatively at 0.2 ㎍/㎏/min (group1 and 2) group 1 (Active Comparator, sevoflurane)will be infused propofol intraoperatively.~group 2(Experimental, propofol) will be inhaled sevoflurane intraoperatively.
Study NCT01189721 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol, sevoflurane
Description: Remifentanil will be infused intraoperatively at 0.2 ㎍/㎏/min (group1 and 2) group 1 (Active Comparator, sevoflurane)will be infused propofol intraoperatively.~group 2(Experimental, propofol) will be inhaled sevoflurane intraoperatively.
Study NCT03566680 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orthokeratology
Description: Orthokeratology is a type of contact lens that is worn over night to reduce refractive error, so patients do not need to wear vision correction during the day.
Study NCT00660374 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin NPH
Description: Soft-treat-to-target dose titration scheme, injection s.c.
Study NCT00660374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EX1000
Description: Soft-treat-to-target dose titration scheme, injection s.c.
Study NCT02446509 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation
Description: Caregivers will meet once a week for 90-minute sessions in a group setting. Dates and times of the group sessions will be arranged according to the convenience of the subjects. The major content will include the causes of bipolar disorder, signs and symptoms of bipolar disorder, the role of stress and life events, types of medications and what they do, self-management of the disorder, understanding the course of the disorder, genetic and biological predispositions, how the family can help, management of relapse.
Study NCT02446509 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation - Delayed
Description: The wait list control group will receive the same intervention as the experimental group, but 7 weeks later.
Study NCT03025009 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC.
Study NCT02577497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: beclomethasone
Study NCT02577497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone
Study NCT04490161 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intravenous reinstallation of cerebrospinal fluid
Description: 10ml of CSF will be taken under sterile conditions from the external ventricular drain and immediately administered intravenously.
Study NCT03672643 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Crizotinib
Description: receive crizotinib orally
Study NCT04430192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-PSMA-617
Description: Patients 1-10 will be given 5GBq of 177Lu-PSMA. Patients 11-20 will be given 2 cycles of 5GBq of 177Lu-PSMA, separated by 6 weeks.
Study NCT05029700 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined exercise training
Description: Combined exercise group (CEG) performed 30 minutes of aerobic training and also received trunk stabilization training in about 30 minutes after a 10-minute resting period. CEG received treatment 2 times a week for 8 weeks. During trunk stabilization training, the participants were taught how to contract the transversus abdominis and multifidus muscles. Due to the progression protocol, endurance levels of trunk muscles were increased by holding each posture for longer periods. The training was started with theraband resistance, which could be repeated between 10-12 repetitions, and the repetition time was increased up to 20. Aerobic training (AT) was given using a treadmill. A heart rate monitor (Polar V800™, Finland) was used by each patient to follow heart rates during the AT. During AT, the target heart rate was calculated as 60-80% of maximum heart rates (MHR). Each exercise session consisted of a 5-minutes warm-up, 20 minutes of walking, and 5 minutes cool down on the treadmill.
Study NCT02786927 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inhaler Preference Questionnaire Version 1
Description: Consists of 5 questions to assess subjects' preference of device attributes and dosing regimens. The two versions of the questionnaire ask the same questions, but differ in the ordering of inhalers in their responses.
Study NCT05029700 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic training
Description: Control group (CG) performed 30 minutes of aerobic training.CG received treatment 2 times a week for 8 weeks. Aerobic training (AT) was given using a treadmill. A heart rate monitor (Polar V800™, Finland) was used by each patient to follow their heart rates during the AT. During AT, the target heart rate was calculated as 60-80% of maximum heart rates (MHR). Each exercise session consisted of a 5-minutes warm-up, 20 minutes of walking, and 5 minutes cool down on the treadmill.
Study NCT05029700 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic training
Description: Control group (CG) performed 30 minutes of aerobic training.CG received treatment 2 times a week for 8 weeks. Aerobic training (AT) was given using a treadmill. A heart rate monitor (Polar V800™, Finland) was used by each patient to follow their heart rates during the AT. During AT, the target heart rate was calculated as 60-80% of maximum heart rates (MHR). Each exercise session consisted of a 5-minutes warm-up, 20 minutes of walking, and 5 minutes cool down on the treadmill.
Study NCT03992729 — intervention group
Intervention type: DRUG
Intervention: Pregnant women exposed to tildrakizumab
Description: Subjects exposure to tildrakizumab for the treatment of an approved indication, for any number of days, at any dose, and at any time from the first day of the last menstrual period (LMP) up to and including the end of pregnancy